Announcement PDF ASX Announcement Appendix 4D: Preliminary Financial Report under ASX Listing Rule 4.2A Current reporting period: Half-year ended 31 December 2023 Prior corresponding period: Half-year ended 31 December 2022 Results for announcement to the market $’000 Revenue from continuing operations (Appendix 4D item 2.1) Up (increase) Adjusted Revenue* Down (excluding Mundipharma settlement) Loss from continuing operations after tax attributable to members (Appendix 4D item 2.2) Loss for the period attributable to members (Appendix 4D item 2.3) Adjusted Loss* (excluding Mundipharma settlement) (decrease) 399% to $8,025 8% to $1,472 88% to $1,034 88% to $1,034 8% to $7,587 Down (decrease) Down (decrease) Down (decrease) *Adjusted Revenue is calculated as Revenue ($8,025,000) from continuing operations less nonrecurring revenue of $6,553,000 relating to the commercial settlement and termination of the VivaGel® BV license and supply agreement with Mundipharma in August 2023. Adjusted Loss likewise subtracts the above nonrecurring revenue from the Loss for the period. Dividends (Appendix 4D items 2.4 and 2.5) No dividends have been paid or declared by the entity since the beginning of the current reporting period. No dividends were paid for the previous corresponding period. No record date for determining entitlements to dividends has been declared. Explanation of Revenue (Appendix 4D item 2.6) Revenue of $8,025,000 (31 December 2022: $1,607,000) for the half-year includes product sales, royalty and license, and research revenue from commercial partners of $7,197,000 (31 December 2022: $1,086,000), and interest income on cash invested in term deposits of $828,000 (31 December 2022: $521,000). Revenue included a nonrecurring $6,553,000 from the commercial settlement of the VivaGel® BV license and supply agreement with Mundipharma in August 2023. Excluding the Mundipharma settlement, half-year adjusted revenue was $1,471,000, an 8% decrease on prior corresponding period revenues, with lower product sales in the current period. For further details, refer to the Interim Report which follows this announcement. Explanation of Loss (Appendix 4D item 2.6) The loss after tax was $1,034,000 (31 December 2022: $8,277,000 loss) and includes nonrecurring revenue of $6,553,000 from the Mundipharma commercial settlement. The half-year includes research and product development expense of $5,263,000 (31 December 2022: $5,599,000) net of the Australian Government’s R&D tax incentive. Research expenditures are primarily associated with the internal DEP® drug delivery programs including DEP® docetaxel, DEP® cabazitaxel, DEP® irinotecan, DEP® ADCs and DEP® radiotheranostics, and the VIRALEZE™ post-market study. For further details, refer to the Interim Report which follows this announcement. Net Tangible Asset Backing (Appendix 4D item 3) Net tangible asset (NTA) backing per ordinary share at 31 December 2023 is $0.08 (31 December 2022: $0.10). The above NTA backing calculation is considered a non-IFRS value and has not been audited or reviewed in accordance with Australian Accounting Standards. Appendix 4D items 4,5,6,7,8,9 are not applicable. This report is based on the consolidated 2023 half-year financial statements which have been reviewed by PricewaterhouseCoopers (the Company’s auditor) with the Independent Auditor’s Review Report included within the 31 December 2023 half-year financial statements. This information should be read in conjunction with the 30 June 2023 Annual Report and any public announcements made by Starpharma Holdings Limited during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001. ASX Announcement Interim Report and Half-Year Financial Results • Strong cash position with $32.1M as at 31 December 2023. Reported half-year revenue of $8M (H1 FY23 $1.6M), including $6.6M VivaGel® BV settlement from Mundipharma. The reported loss for the period was $1.0M (H1 FY23 $8.3M). • Phase 2 clinical trials of DEP® cabazitaxel, DEP® docetaxel, and DEP® irinotecan showed positive results in treating multiple cancer types, providing further clinical validation of the DEP® platform and highlighting its value proposition in repurposing and enhancing the therapeutic and commercial utility of widely used cancer therapies. • The DEP® platform showed imaging benefits in targeted radio diagnostic approaches. Specifically, DEP® HER2-zirconium demonstrated a favourable biodistribution profile, rapid uptake, and high levels of tumour accumulation in a HER2+ breast cancer model. • Results from the Viraleze™ post-market study in participants with COVID-19 showed antiviral efficacy, with effects more pronounced in the older patient cohorts. Viraleze™ achieved a statistically significant reduction in SARS-CoV-2 viral load in the cohort of participants aged 45 and over. The clinical evidence generated by the Viraleze™ post-market study will support ongoing commercial and regulatory activities. • Following Starpharma’s successful commercial settlement agreement with Mundipharma for VivaGel® BV and the subsequent reversion of territorial rights over the product, Starpharma signed a regional sales and distribution agreement for VivaGel® BV with ITROM Pharmaceutical Group, covering 13 countries across the Middle East and North Africa (MENA) region. Melbourne, Australia; 28 February 2024: Starpharma (ASX: SPL, OTCQX: SPHRY) today releases its Interim Report and Half-Year Financial Results for the period ended 31 December 2023 (H1 FY24). Starpharma’s Chief Executive Officer, Cheryl Maley, commented: “Starpharma has made important progress towards achieving its objectives during this half. This includes completing and reporting the results from the Phase 2 clinical trials of its DEP® candidates and the clinical study of Viraleze™. The Company also presented the DEP® platform at multiple industry conferences and executed a new VivaGel® BV partnership in the Middle East and North Africa region. “Starpharma is focused on advancing its DEP® platform towards commercialisation and building partnerships and collaborations. The DEP® platform is highly versatile and can be applied to a wide range of novel therapeutics, including but not limited to Antibody-Drug Conjugates (ADCs) and radiotheranostics, offering a range of therapeutic and commercial benefits. This is supported by the Phase 2 proof-of-concept clinical trial results and the early data in ADCs and radiotheranostics. “In parallel, Starpharma is committed to leveraging the existing approvals of VivaGel® BV and Viraleze™ to expand their brand recognition and sales. “With a strong cash balance of $32.1 million (at 31 December 2023), Starpharma is well-positioned to move forward with its pipeline and will allocate its resources in line with its strategic priorities.” DEP® Programs The final results from the Phase 2 clinical trial programs of DEP ® cabazitaxel and DEP® docetaxel were reported. Recruitment for the Phase 2 clinical trial of DEP® irinotecan was completed, and interim results were reported. Multiple scientific posters highlighting the DEP® platform were also accepted for presentation at international cancer research conferences. The DEP® cabazitaxel Phase 2 clinical trial met its objectives, with endpoints demonstrating antitumour efficacy in advanced, metastatic castration-resistant prostate cancer, platinum-resistant ovarian cancer, and gastro-oesophageal cancers. The trial also confirmed the safety and tolerability of DEP® cabazitaxel. The key results from the Phase 2 trial of DEP® cabazitaxel in patients with advanced gastrooesophageal cancers were presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in the US in January 2024. The DEP® docetaxel Phase 2 clinical program demonstrated encouraging anti-tumour activity in multiple advanced, metastatic cancers, including pancreatic cancer, gastro-oesophageal cancer, non-small cell lung cancer, and cholangiocarcinoma. The safety and tolerability of DEP® docetaxel were also confirmed. These results were demonstrated in the monotherapy and combination arms, where DEP® docetaxel was administered either as a monotherapy or combination therapy with other anti-cancer agents, nintedanib or gemcitabine. The interim clinical data on DEP® irinotecan showed durable anti-tumour responses in advanced colorectal cancer and platinum-resistant/refractory ovarian cancer and good tolerability across the study. Enrolment has been completed for both the monotherapy and combination arms. Several patients with advanced cancers, including ovarian and colorectal cancers, are continuing therapy and are experiencing prolonged responses to treatment and significant clinical benefits. These interim data on DEP® irinotecan were presented at the International Conference on Molecular Targets and Cancer Therapeutics, co-hosted by the American Association of Cancer Research (AACR), National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC) in the US in October 2023. Additional nonclinical data on DEP ® irinotecan in combination with immuno-oncology agents were also presented at this conference. The DEP® radiotheranostics program made progress, with Starpharma’s HER2-targeted radiodiagnostic candidate, DEP® HER2-zirconium, demonstrating a favourable biodistribution profile with excellent imaging contrast between tumour and normal tissues, as well as rapid uptake and high levels of tumour accumulation in a HER2-positive (HER2+) breast cancer model. These data were also presented at the AACR-NCI-EORTC Conference in the US in October 2023. The application, versatility, and benefits of the DEP® platform for targeted delivery of radiotheranostics, including an overview of Starpharma’s two DEP® HER2-targeted radiotheranostic products, DEP® HER2-zirconium and DEP® HER2-lutetium, were also presented at the Targeted Radiopharmaceuticals Summit in Berlin in December 2023. On 31 July 2023, following communication from AstraZeneca on 28 July 2023 and the subsequent release of their H1 and Q2 2023 results announcement that day, Starpharma reported that AstraZeneca had made the decision to discontinue the development of AZD0466 after an internal review prompted by a small number of asymptomatic adverse events that were unrelated to Starpharma’s dendrimer drug delivery technology. Starpharma’s in-house preclinical DEP® Antibody-Drug Conjugates (ADCs) programs continued progressing alongside our partnered programs, including MSD and Genentech. The Company’s partner programs involve a number of therapeutic areas, including ADCs. A key focus for Starpharma is advancing its DEP® platform and assets towards commercialisation through partnerships and licensing. The Company is actively supporting its existing partners and, in parallel, is seeking and targeting new partnerships to leverage its dendrimer technology. 2 Viraleze™ and VivaGel® BV The results of the post-market clinical study of Viraleze™ nasal spray in participants with COVID19 were reported in January 2024. Viraleze™ achieved a statistically significant reduction in SARSCoV-2 viral load in the cohort of participants aged 45 and over. Other antiviral effects were also observed, including increased viral clearance rate from the nose, reduced time to negative PCR1 test and improvement in key symptoms, including recovery from loss of smell. As seen in a previously announced trial in healthy volunteers, Viraleze™ was well-tolerated. The results from the Viraleze™ clinical study provide significant clinical evidence of the performance of Viraleze™ that will support regulatory processes for the transition to the new European Medical Device Regulations (MDR), which will come into full effect in 2029. The data will also support ongoing marketing and commercial activities for the product. Starpharma continues to market Viraleze™ online through Amazon and dedicated product websites. Starpharma also has commercial partners in several international markets, where the product is distributed online and in retail outlets, including pharmacies. Viraleze™ is not approved for use or supply in Australia, where the review by the Therapeutic Goods Administration (TGA) for the SPL7013 nasal spray as a medical device is ongoing. In February 2024, Starpharma completed the formal dispute resolution process with the US Food and Drug Administration (FDA) in relation to VivaGel® BV. The FDA maintained its position that they require additional clinical efficacy data to be generated for the regulatory approval of VivaGel® BV for bacterial vaginosis (BV) in the US. Starpharma is not planning to pursue additional clinical studies for VivaGel® BV on its own at this time but remains committed to leveraging the VivaGel® BV development program and will work to maximise the commercial potential for VivaGel ® BV in the more than 45 markets where it is already approved. The decision by the FDA does not alter the approval status in the countries where VivaGel® BV is already registered. In January 2024, Starpharma partnered with ITROM Pharmaceutical Group for the sales and distribution of VivaGel® BV across 13 countries in the Middle East and North Africa region. ITROM has a strong presence throughout the region’s public and private health sectors, maintaining strong relationships with key opinion leaders, specialist physicians, hospital chains and retail outlets. This new partnership with ITROM followed the reversion of VivaGel® BV rights to Starpharma under a settlement agreement with Mundipharma in August 2023. Under the settlement, Starpharma received a $6.6M cash payment from Mundipharma in August 2023, and the VivaGel® BV commercial rights reverted to Starpharma. Starpharma’s partner, Aspen, continues to market VivaGel® BV in Australia and New Zealand. In Australia, VivaGel® BV is the number 1 topical brand by sales for the treatment of BV and prevention of BV recurrence. The Company continues pursuing additional commercial opportunities for the Viraleze™ and VivaGel® BV products. Starpharma and Okamoto signed a contract extension for the VivaGel® Condom product. This agreement covers Japan and several other Asian markets. Okamoto continues marketing in Japan and regulatory activities in a number of other Asian markets. Financial Summary Half-year revenues were $8.0M, including revenue from commercial partners of $7.2M (H1 FY23: $1.1M) and interest income of $0.8M (H1 FY23: $0.5M). Revenue included a nonrecurring $6.6M from the commercial settlement of the VivaGel® BV licence and supply agreement with 1 Polymerase chain reaction. 3 Mundipharma in August 2023. Excluding the Mundipharma settlement, the half-year adjusted revenue was $1.5M, an 8% decrease on H1 FY23, with lower product sales in the current period. The half-year loss after tax was $1.0M (H1 FY23: $8.3M) and includes research and product development expenses of $5.3M (H1 FY23: $5.6M) net of the Australian Government’s R&D tax incentive. Research expenditures were primarily associated with Starpharma’s internal DEP® drug delivery programs, including DEP® docetaxel, DEP® cabazitaxel, DEP® irinotecan, DEP® ADCs and DEP® radiotheranostics, and the Viraleze™ post-market study. During the period, Starpharma received a $7.2M R&D tax incentive and repaid the $4.0M lowinterest R&D loan with the Treasury Corporation of Victoria. Starpharma’s balance sheet remains strong, with a closing cash position of $32.1M at 31 December 2023. About Starpharma Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is a world leader in dendrimer technology for medical applications. As an innovative Australian biopharmaceutical company, Starpharma is focused on developing and commercialising novel therapeutic products that address significant global healthcare needs. Starpharma boasts a strong portfolio of products, partnerships, and intellectual property. Starpharma’s innovative technology is based on proprietary polymers called dendrimers, which are precise, synthetically manufactured, nanoscale molecules. The unique properties of dendrimers – including their size, structure, high degree of branching, polyvalency, and water solubility – are advantageous in medical and pharmaceutical applications. Starpharma uses its dendrimer technology to develop novel therapeutics and to improve the performance of existing pharmaceuticals. Starpharma’s portfolio includes multiple clinical-stage oncology products, which utilise its Dendrimer Enhanced Product (‘DEP ®’) drug delivery technology, and marketed products, including VIRALEZE™ and VivaGel® BV, which utilise SPL7013, a proprietary dendrimer with antimicrobial properties. Starpharma’s DEP® drug delivery platform is being used to enhance the effectiveness of existing and novel therapies and to reduce drug-related toxicities through controlled and specified drug delivery. In addition to Starpharma’s internal DEP® programs, Starpharma has multiple DEP® partnerships with international biopharmaceutical companies, including AstraZeneca (oncology), MSD (Antibody-Drug Conjugates), Chase Sun (anti-infectives), and other world-leading pharmaceutical companies. Due to the broad applicability and optionality of Starpharma’s DEP ® platform, partnered DEP® programs have the potential to generate significant future milestones and royalties. Starpharma’s topical nasal spray, Viraleze™, is registered in more than 35 countries, including Europe, the UK, and Asia. Starpharma’s novel nonantibiotic vaginal gel, VivaGel® BV, for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV, is registered in more than 50 countries, including in the UK, Europe, Southeast Asia, South Africa, Australia and New Zealand. For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on LinkedIn. WE Communications Hannah Howlett +61 450 648 064 WE-AUStarPharma@weworldwide.com Starpharma Holdings Limited Cheryl Maley, Chief Executive Officer Justin Cahill, CFO and Company Secretary +61 3 8532 2704 investor.relations@starpharma.com 4-6 Southampton Crescent Abbotsford Vic 3067 Disclosure This ASX Announcement was authorised for release by the Chair, Mr Rob Thomas. Forward-Looking Statements This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product. 4 Starpharma Holdings Limited ABN 20 078 532 180 Interim Report FOR THE HALF-YEAR ENDED 31 DECEMBER 2023 This information should be read in conjunction with the 30 June 2023 Annual Report and any public announcements made by Starpharma Holdings Limited during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001. Contents Directors’ Report 2 Auditor’s Independence Declaration 6 Interim Financial Report 7 Independent Auditor’s Review Report to the Members 16 Interim Report – 31 December 2023 Starpharma Holdings Limited 1 Directors’ Report The directors are pleased to present this report on the consolidated entity (referred to hereafter as the “Group”, “Company”, or “Starpharma”) consisting of Starpharma Holdings Limited (the “Parent Entity”) and the entities it controlled at the end of, or during, the half-year ended 31 December 2023. Directors The following persons were directors of Starpharma Holdings Limited during the whole of the half-year and up to the date of this report unless otherwise stated: R B Thomas, AO (Chairman) L Cheng D J McIntyre J R Davies R Basser J K Fairley (retired as Chief Executive Officer and Managing Director on 8 January 2024) C Maley (appointed as Chief Executive Officer and Managing Director on 8 January 2024) Principal Activities The principal activities of the Group consist of research, development and commercialisation of dendrimer products for pharmaceutical and healthcare applications. Activities within the Group are directed towards the development of precisely defined nano-scale materials, including the development of SPL7013 (astodrimer sodium) as a vaginal gel, VivaGel® BV, for the management of bacterial vaginosis; Viraleze™ antiviral nasal spray; and as an antiviral condom coating. Starpharma is also applying its proprietary dendrimers to drug delivery to create improved pharmaceuticals and has developed the valuable DEP® (Dendrimer Enhanced Product) delivery platform. Strategy, Future Developments and Prospects The Company aims to generate value through the clinical development and commercialisation of its proprietary products, as well as partnerships with pharmaceutical and biotechnology companies based on its patented dendrimer technology in pharmaceutical and healthcare applications. The Company’s key focus is to advance its DEP® programs and to fully leverage partnerships in target markets for VivaGel® and Viraleze™. Starpharma intends to achieve this by continuing to utilise a combination of internally funded and partnered projects across its dendrimer portfolio. The Company commercialises its development pipeline with corporate partners via licensing, and sales and distribution agreements at various stages in a product’s development lifecycle; depending on the product, patent opportunity, a partner’s commercial strategy and relative strength of product and market expertise, comparison of current and future potential returns. Starpharma has extensive expertise, a strong intellectual property portfolio, a diverse product portfolio, and a strong cash position. Going forward, Starpharma’s strategy is to extract the highest value from its patented DEP® technology, as well as its marketed products VivaGel® BV and Viraleze™. Efforts to achieve this will be increasingly focused on key markets and supported by a strengthened commercial capability. Dividends No dividends have been paid or declared by the Company during the current reporting period. No dividends were paid for the previous corresponding period. Review of Operations DEP® Drug Delivery Platform Starpharma’s DEP® platform is being used to enhance the therapeutic utility of drugs through improved solubility, efficacy and pharmacokinetic control, and reductions in certain drug-related toxicities. Starpharma’s innovative and proprietary DEP® platform has shown advantages across a wide range of drug classes. It has the potential to provide benefits to small molecule drugs, peptides and proteins and in the development of DEP® Antibody-Drug Conjugates (ADCs) and radiotheranostics. The dendrimer technology could provide benefit to companies looking to extend patents of key drugs in their portfolio or looking to enhance the outcome of a drug currently in development to improve efficacy and / or reduce toxicity. Key activities until the date of this report include: The final results from the Phase 2 clinical trial programs of DEP® cabazitaxel and DEP® docetaxel were reported. Recruitment for the Phase 2 clinical trial of DEP® irinotecan was completed, and interim results were reported. The DEP® cabazitaxel Phase 2 clinical trial met its objectives, with endpoints demonstrating positive anti-tumour efficacy in advanced, metastatic castrate-resistant prostate cancer, platinum-resistant ovarian cancer, and gastro-oesophageal cancers. The trial also confirmed the safety and tolerability of DEP® cabazitaxel. Interim Report – 31 December 2023 Starpharma Holdings Limited 2 The key results from the Phase 2 trial of DEP® cabazitaxel in patients with advanced gastro-oesophageal cancers were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in January 2024. The DEP® docetaxel Phase 2 clinical program met its objectives, with endpoints demonstrating encouraging anti-tumour activity in multiple advanced, metastatic cancers, including pancreatic cancer, gastro-oesophageal cancer, non-small cell lung cancer, and cholangiocarcinoma. The safety and tolerability of DEP® docetaxel were also confirmed. These results were demonstrated in the monotherapy and combination arms, where DEP® docetaxel was administered either as a monotherapy or combination therapy with other anti-cancer agents, nintedanib or gemcitabine. The interim clinical data on DEP® irinotecan showed durable anti-tumour responses in advanced colorectal cancer and platinumresistant/refractory ovarian cancer and good tolerability across the study. Enrolment has been completed for both the monotherapy and combination arms. Several patients with advanced cancers, including ovarian and colorectal cancers, are continuing therapy and are experiencing prolonged responses to treatment and significant clinical benefits. These interim data on DEP® irinotecan were presented at the International Conference on Molecular Targets and Cancer Therapeutics, co-hosted by the American Association of Cancer Research (AACR), National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC) in the US (AACR-NCI-EORTC) in October 2023. Additional nonclinical data on DEP® irinotecan in combination with immune-oncology agents were also presented at this conference. The DEP® radiotheranostics program made progress, with Starpharma’s HER2-targeted radiodiagnostic candidate, DEP® HER2zirconium, demonstrating a favourable biodistribution profile with excellent imaging contrast between tumour and normal tissues, as well as rapid uptake and high levels of tumour accumulation in a HER2-positive (HER2+) breast cancer model. These data were also presented at the AACR-NCI-EORTC Conference in October 2023. The application, versatility, and benefits of the DEP® platform for targeted delivery of radiotheranostics, including an overview of Starpharma’s two DEP® HER2-targeted radiotheranostic products, DEP® HER2-zirconium and DEP® HER2-lutetium, were also presented at the Targeted Radiopharmaceuticals Summit in Berlin in December 2023. On 31 July 2023, following communication from AstraZeneca on 28 July 2023 and the subsequent release of their H1 and Q2 2023 results announcement that day, Starpharma reported that AstraZeneca had made the decision to discontinue the development of AZD0466 after an internal review prompted by a small number of asymptomatic adverse events that were unrelated to Starpharma’s dendrimer drug delivery technology. Starpharma’s in-house preclinical DEP® Antibody-Drug Conjugates (ADCs) programs continued progressing alongside our partnered programs, including MSD and Genentech. The Company’s partner programs involve a number of therapeutic areas, including oncology and ADCs. A key focus for Starpharma is advancing its DEP® platform and assets towards commercialisation through partnerships and licensing. The Company is actively supporting its existing partners and, in parallel, is seeking and targeting new partnerships to leverage its dendrimer technology. Viraleze™ and VivaGel® BV Starpharma’s topical nasal spray, Viraleze™, is registered in more than 35 countries, including Europe, the UK, and Asia. (Viraleze™ is not approved for use or supply in Australia). VivaGel® BV, for the treatment of bacterial vaginosis (BV) and prevention of recur